These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
420 related items for PubMed ID: 8089930
21. 5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monamine oxidase type B inhibitors. Mazouz F, Gueddari S, Burstein C, Mansuy D, Milcent R. J Med Chem; 1993 Apr 30; 36(9):1157-67. PubMed ID: 8487255 [Abstract] [Full Text] [Related]
22. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V, Jarreau FX. J Pharmacol Exp Ther; 1996 Apr 30; 277(1):253-64. PubMed ID: 8613928 [Abstract] [Full Text] [Related]
23. Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors. Yu PH, Davis BA, Durden DA, Barber A, Terleckyj I, Nicklas WG, Boulton AA. J Neurochem; 1994 Feb 30; 62(2):697-704. PubMed ID: 8294932 [Abstract] [Full Text] [Related]
24. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. Sagi Y, Weinstock M, Youdim MB. J Neurochem; 2003 Jul 30; 86(2):290-7. PubMed ID: 12871570 [Abstract] [Full Text] [Related]
25. The molecular pharmacology of L-deprenyl. Gerlach M, Riederer P, Youdim MB. Eur J Pharmacol; 1992 Jun 05; 226(2):97-108. PubMed ID: 1639115 [Abstract] [Full Text] [Related]
26. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver. Ozaita A, Olmos G, Boronat MA, Lizcano JM, Unzeta M, García-Sevilla JA. Br J Pharmacol; 1997 Jul 05; 121(5):901-12. PubMed ID: 9222546 [Abstract] [Full Text] [Related]
27. L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse. Thiffault C, Lamarre-Théroux L, Quirion R, Poirier J. Brain Res Mol Brain Res; 1997 Mar 05; 44(2):238-44. PubMed ID: 9073165 [Abstract] [Full Text] [Related]
28. The effect of L-deprenyl, D-deprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity. Thiffault C, Quirion R, Poirier J. Brain Res Mol Brain Res; 1997 Oct 03; 49(1-2):127-36. PubMed ID: 9387872 [Abstract] [Full Text] [Related]
29. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline. Ogunrombi MO, Malan SF, Terre'Blanche G, Castagnoli K, Castagnoli N, Bergh JJ, Petzer JP. Life Sci; 2007 Jul 19; 81(6):458-67. PubMed ID: 17655878 [Abstract] [Full Text] [Related]
30. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N. Pérez V, Morón J, Pastó M, Unzeta M. Neurobiology (Bp); 2000 Jul 19; 8(3-4):231-6. PubMed ID: 11225513 [Abstract] [Full Text] [Related]
31. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Fang J, Yu PH. Neuropharmacology; 1994 Jun 19; 33(6):763-8. PubMed ID: 7936114 [Abstract] [Full Text] [Related]
32. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity. Kinemuchi H, Arai Y, Toyoshima Y. Neurosci Lett; 1985 Jul 31; 58(2):195-200. PubMed ID: 3876524 [Abstract] [Full Text] [Related]
33. Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro. Kan JP, Steinberg R, Leclercq J, Worms P, Biziere K. J Neurochem; 1988 Apr 31; 50(4):1137-44. PubMed ID: 3346672 [Abstract] [Full Text] [Related]
34. The influence of metabolism on the MAO-B inhibitory potency of selegiline. Haberle D, Szökõ E, Magyar K. Curr Med Chem; 2002 Jan 31; 9(1):47-51. PubMed ID: 11860347 [Abstract] [Full Text] [Related]
35. Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO). Herraiz T, Arán VJ, Guillén H. Free Radic Res; 2009 Oct 31; 43(10):975-84. PubMed ID: 19669997 [Abstract] [Full Text] [Related]
36. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons. Rothblat DS, Schneider JS. Brain Res; 1998 Jan 01; 779(1-2):226-30. PubMed ID: 9473679 [Abstract] [Full Text] [Related]
37. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K. J Pharmacol Exp Ther; 1987 Jan 01; 240(1):251-8. PubMed ID: 3100771 [Abstract] [Full Text] [Related]
38. Depletion of heart norepinephrine in mice by some analogs of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Fuller RW, Hemrick-Luecke SK. Res Commun Chem Pathol Pharmacol; 1987 May 01; 56(2):147-56. PubMed ID: 3496637 [Abstract] [Full Text] [Related]
39. Central and peripheral catecholamine depletion by 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in rodents. Fuller RW, Steranka LR. Life Sci; 1985 Jan 21; 36(3):243-7. PubMed ID: 3871244 [Abstract] [Full Text] [Related]
40. Design and early clinical evaluation of selective inhibitors of monoamine oxidase. Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A. Prog Neuropsychopharmacol Biol Psychiatry; 1988 Jan 21; 12(6):967-87. PubMed ID: 3266532 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]